Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.
The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions. Viking conducts Phase 2 clinical trials for these candidates, evaluating safety, tolerability and efficacy across multiple patient populations.
Viking Therapeutics maintains operations across the United States, engaging with clinical research sites to enroll patients in its ongoing studies. The company also collaborates with academic institutions and regulatory agencies to advance trial designs and biomarker strategies that support its drug development objectives.
Under the leadership of President and Chief Executive Officer David A. Woodhouse, Viking has built a management team with extensive experience in endocrinology, metabolic disease and biopharmaceutical development. The company’s strategic focus remains on progressing its pipeline through clinical milestones and exploring opportunities to extend its proprietary technology platform into additional indications.
AI Generated. May Contain Errors.
